|
ImClone Systems Inc.
|
180 Varick Street
New York, NY 10014-4606
United States |
| Tel: |
1/212 645-1405 |
| URL: |
http://www.imclone.com |
|
 |
| Primary Symbols & Exchanges: |
| IMCL - NASDAQ |
|
|
| Primary Industry: |
| Biotechnology |
|
|
SIC Industry Code:
|
|
NAICS Industry Code:
|
|
Thomson Financial Business Description:
| The Group's principal activity is to conduct research and develop therapeutic products for the treatment of cancer and cancer related disorders. The Group's product, ERBITUX(TM) is a therapeutic monoclonal antibody that inhibits stimulation of Epidermal Growth Factor (EGF) receptor upon which certain solid tumors depend in order to grow. The Group also develops the inhibitors of angiogenesis, which can be used to treat various kinds of cancer and other diseases. The Group performs ongoing research which includes ongoing clinical programs of growth factor blockers, other tumor cell growth inhibitors and angiogenesis inhibitors. |
|
Alacra Alerts:
 
|
Receive alerts on the latest reports on ImClone Systems Inc.
Subscribe to Alacra Alerts via RSS and never miss the latest research on your favorite companies. Just click the images above to add the feed directly to your favorite newsreader.
|
|
